Medivir Abandons Separate Listing, Sells Off Commercial Unit
Executive Summary
Medivir has decided a sale of its commercial arm BioPhausia makes better business sense than a separate listing, and is selling the unit to Karo Pharma for just over $100m.
You may also be interested in...
Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects
Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.
Medivir's Oncology Asset Purchase Seals TetraLogic's Death
Medivir, which recently reinvented itself as a solely oncology-based R&D company, is buying two programs for TetraLogic which will subsequently 'terminate all remaining employees'.
Medivir Plans For A Post-Simeprevir Future
The hepatitis C therapy simeprevir may have been a commercial success for the small Swedish biotech Medivir, but as competition increases and sales decline, the company is planning for what comes next.